CRISPR Posts $99 Million Casgevy Sales

CRISPR Therapeutics reported a wider net loss in the third quarter as its gene-editing therapy Casgevy generated its first sales-driven revenue growth.

Updated on Nov. 2, 2026 in Biotech

A clean, sparse laboratory bench with a glass flask of pale amber liquid beside a closed centrifuge in soft daylight. — CRISPR Therapeutics reported third-quarter Casgevy sales of $99 million, up 30% from the prior quarter, as its gene-editing therapy with partner Vertex began generating sales-driven revenue growth. AI Illustration. Upload story photo >

CRISPR Therapeutics reported third-quarter 2026 Casgevy sales of $99 million, up 30% from the second quarter and nearly six times the year-ago quarter. The company's shares fell about 2% in early after-hours trading.

Why it matters

CRISPR does not book Casgevy sales itself, since Vertex runs the launch and the two companies split profits and costs 60/40. Its reported net loss widened to $111.4 million, partly because other income fell by about $7.5 million.

CRISPR's third-quarter filing shows Casgevy sales of $99 million, up 30% from the prior quarter, with cash and marketable securities of $2.28 billion versus $1.98 billion at the end of 2025. Net collaboration expense fell about 28% year over year, though the company did not address the longer-term sales trajectory in the extraction.

The players

CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company whose Casgevy therapy is co-developed and commercialized with Vertex Pharmaceuticals.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a biotechnology company that runs the Casgevy launch and shares profits and costs with CRISPR under a 60/40 split.

The details

Collaboration revenue reached $12.3 million, compared with none a year earlier. Cash rose partly because CRISPR sold $585 million of convertible notes in March.

March 2026: CRISPR sold $585 million of convertible notes.
Third quarter 2026: Casgevy reported $99 million in sales.
Nov. 9, 2026: CTX310 Phase 1b data in severe hypertriglyceridemia is set for a late-breaking talk at the American Heart Association meeting.

Roadmap

Casgevy is among the first commercial CRISPR-based gene-editing therapies, and its sales ramp marks an early test of whether gene editing can sustain a revenue base. The partnership structure with Vertex shows how gene-therapy companies are sharing commercialization costs to reach patients.

Casgevy's availability and pricing depend on the commercial partnership between CRISPR and Vertex, which determines how the therapy reaches patients. The sales growth signals broader patient access as the therapy moves beyond its initial launch phase.

The takeaway

Commercial gene-editing therapies depend on partnership structures that divide costs and profits, and early sales growth can narrow a company's net loss even as its underlying operations remain costly. Readers tracking biotech should watch whether Casgevy's sales momentum continues in future quarters.

What happens next

CTX310 Phase 1b data in severe hypertriglyceridemia will be presented at a late-breaking talk at the American Heart Association meeting on Nov. 9, 2026.